ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) reached a new 52-week low during trading on Monday . The company traded as low as $0.37 and last traded at $0.42, with a volume of 396900 shares. The stock had previously closed at $0.43.

Separately, Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of ContraVir Pharmaceuticals in a research note on Thursday, August 24th.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. raised its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,414,475 shares of the biopharmaceutical company’s stock after acquiring an additional 366,192 shares during the period. Vanguard Group Inc. owned approximately 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent SEC filing. Institutional investors own 6.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ContraVir Pharmaceuticals (CTRV) Hits New 52-Week Low at $0.37” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at

About ContraVir Pharmaceuticals

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.